TAKEDA-PHARMACEUTICAL
10.5.2016 08:03:15 CEST | Business Wire | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502):
| FY2015: A year of turnaround to sustained growth; achieved full year management guidance | |||
|
• |
Underlying revenue up +3.4% (reported revenue growing +1.7% to 1,807.4 billion yen), led by strong performances in Takeda's growth drivers (GI, Oncology, CNS and Emerging Markets) |
||
|
• |
Underlying Core Earnings up +8.1% (reported operating profit recorded 130.8 billion yen), aided by cost discipline |
||
|
• |
Underlying Core EPS up +21.7% (reported EPS was 102 yen), growing 2.5x faster than underlying core earnings |
||
| Growth Drivers continued to be robust | |||
|
• |
Consolidated underlying revenue growth of Gastroenterology (GI), Oncology, Central Nervous System (CNS) and Emerging Markets – Takeda's Growth Drivers – was +9.5% year-to-year |
||
|
• |
Underlying revenue of GI +23.6%, Oncology +1.0%* and CNS +37.3% year-to-year |
||
|
• |
Emerging Markets underlying revenue +4.8% year-to-year with continued growth in the key markets of China, Russia and Brazil |
||
|
*Underlying growth of Oncology excluding VELCADE royalties was +4.4% |
|||
|
Broad portfolio of growing products offsets loss of exclusivity decline |
|||
|
• |
ENTYVIO(®) is on track to exceed $2 billion MAT* sales within FY2018 |
||
|
• |
Encouraging uptake of NINLARO(®) and TAKECAB(®) |
||
|
• |
BRINTELLIX(®) and ADCETRIS(®) showed continued growth |
||
|
• |
AZILVA(®) and LOTRIGA(®) are contributing to the Japan business |
||
|
*Moving Annual Total @ constant currency |
|||
| Efficiency gains continue | |||
|
• |
Project Summit well exceeded full-year target resulting in 30 billion yen additional cost savings |
||
|
• |
Strong cash flow performance with Operating Free Cash Flow, excluding Actos settlement payment, reaching 230 billion JPY |
||
| FY2016 management guidance: A year of strategic focus to sustain growth | |||
|
• |
Underlying Revenue: Mid-single digit growth (%) |
||
|
• |
Underlying Core Earnings: Low- to mid-teen growth (%) |
||
|
• |
Underlying Core EPS: Low- to mid-teen growth (%) |
||
Christophe Weber, President and Chief Executive Officer of Takeda,
commented:
"FY2015 was a turnaround year. We achieved our
management guidance for the second consecutive year, led by our growth
drivers, and aided by the global launches of new products such as
ENTYVIO and NINLARO. Takeda will continue to deliver innovative new
medicines to patients, especially in our focused R&D therapeutic areas.
Takeda aims to relentlessly execute our strategic roadmap to deliver our
long-term aspiration, and will serve the needs of the patients, with the
best in class agility and innovation."
|
|
|||||||||
|
Key figures for the full |
year of FY2015 (April 2015 –March 2016) |
||||||||
| FY 2014 | FY 2015 | Growth | |||||||
| (billion yen) | Underlying2 | ||||||||
| Revenue | 1,777.8 | 1,807.4 | +1.7% | +3.4% | |||||
| Operating Profit | -129.3 | 130.8 | – | – | |||||
| Core Earnings 1 | 288.3 | 292.4 | +1.4% | +8.1% | |||||
| Net Profit 3 | -145.8 | 80.2 | – | – | |||||
| EPS | -185 yen | 102 yen | – | – | |||||
| Core EPS | 225 yen | 258 yen | +14.8% | +21.7% | |||||
|
1 |
Core Earnings is calculated from operating profit by excluding the impact of exceptional items, such as purchase accounting, amortization and impairment loss of intangible assets, restructuring costs and major litigation costs. | |
|
2 |
Underlying performance aims at understanding the real performance of the business. Underlying Revenue, Underlying Core Earnings, and Underlying Core EPS exclude the same as above and adjusted for acquisitions/divestments and foreign exchange. | |
|
3 |
Attributable to the owners of the company | |
Underlying revenue growth was mainly driven by Takeda's Growth Drivers: Gastroenterology(GI), Oncology, and Central Nervous System (CNS) in addition to Emerging Markets. The Growth Drivers account for 52% of Takeda's revenue. GI revenue grew by +23.6% year-to-year, driven by ENTYVIO® . Oncology revenue increased by +1.0%, contributed by VELCADE® , ADCETRIS® and NINLARO® , which has shown an encouraging start in the U.S. since it was launched in December,. Oncology revenue excluding VELCADE royalties grew +4.4%. CNS revenue, including BRINTELLIX® , increased by +37.3%. Emerging Markets revenue grew by +4.8% year-to-year, led by Value Brands (branded generics and Over-The-Counter medicines), with steady growth in China (+11.1%), Russia (+6.2%) and Brazil (+5.7%). However, our future aspiration for growth in Emerging Markets remains strong, in high single digits. Performance in the U.S. (+12.4% year-to-year underlying revenue growth) also contributed to total revenue growth. In Japan, which remains under increasing generic pressure, underlying revenue declined -3.3% year-to-year, but AZILVA® and LOTRIGA® showed significant sales growth of +30.1% and +69.0%, respectively, year-to-year. In addition to these growing products, TAKECAB® and ZAFATEK® are expected to be key sales drivers in Japan after the lifting of the 2-week limit on the prescription period.
Consolidated operating profit was 130.8 billion yen, an increase of 260.1 billion yen compared to the previous year, which exceeded the raised forecast of 120 billion yen announced in February at the FY2015 3rd quarter earnings announcement. Selling, general and administrative expenses increased by 38.2 billion yen (+6.2%) compared to the previous year, mainly due to the increase in sales expenses related to new products in the U.S., but R&D expenses decreased by 36.2 billion yen (-9.5%). Amortization and impairment losses on intangible assets associated with products decreased by 51.3 billion yen (-29.1%), mainly due to 30.5 billion yen of COLCRYS® impairment loss being recognized in 2014 compared to an 8.6 billion yen impairment reversal in fiscal 2015. Other operating income decreased by 82.1 billion yen (-76.6%), mainly due to 53.8 billion yen of revaluation of COLCRYS® contingent consideration liability and 32.8 billion yen of the gains on sales of real estate being recognized in the previous year. Other operating expenses decreased by 277.8 billion yen (-86.2%), mainly due to 274.1 billion yen of loss on Actos litigation in the U.S. being recognized in the previous year.
Project Summit – a company-wide strategic initiative to increase efficiency – continued to produce results, with 30 billion yen of additional savings in FY2015, exceeding the full year target as a result of higher Procurement savings.
As part of its ongoing effort to improve R&D productivity, Takeda is focusing on its core therapeutic areas of Oncology, GI and CNS. Takeda will further strengthen its initiatives and commitment to lead innovation in medicines and provide innovative new drugs to patients around the world including in emerging markets.
FY2015 was positioned for Takeda as a year of turnaround to sustained growth, and Takeda sets the following management guidance for FY2016 as a year of strategic focus to sustain growth.
|
Management Guidance for FY2016 |
|||
| Underlying Growth (%) | |||
| Underlying Revenue | Mid-single digit | ||
| Underlying Core Earnings | Low- to mid-teen | ||
| Underlying Core EPS | Low- to mid-teen | ||
| Dividend per Share | 180 yen | ||
|
Reported Forecast for FY2016 |
(change vs. FY2015 results) |
|||
| billion yen | FY 2016 1 | Change | ||
| Revenue | 1,720.0 | -4.8% | ||
| R&D expenses | 325.0 | -6.0% | ||
| Operating Profit | 135.0 | +3.2% | ||
| Net Profit 2 | 88.0 | +9.8% | ||
| EPS | 112 yen | +9.8% | ||
| 1 | The exchange rate assumptions for FY2016 are 1US$=110 yen and 1 euro=125 yen | |
| 2 | Attributable to the owners of the company | |
For more details on Takeda’s FY2015 full year results and other financial information, please visit http://www.takeda.com/investor-information/results/
About Takeda Pharmaceutical Company Limited
Takeda
Pharmaceutical Company Limited (TOKYO:4502
)
is a global, R&D-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating science
into life-changing medicines. Takeda focuses its research efforts on
oncology, gastroenterology and central nervous system therapeutic areas.
It also has specific development programs in specialty cardiovascular
diseases as well as late-stage candidates for vaccines. Takeda conducts
R&D both internally and with partners to stay at the leading edge of
innovation. New innovative products, especially in oncology, central
nervous system and gastroenterology, as well as its presence in emerging
markets, fuel the growth of Takeda. More than 30,000 Takeda employees
are committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160509006801/en/
Contact:
Takeda Pharmaceutical Company Limited
Investor Relations
Noriko
Higuchi, +81-(0)3-3278-2306
noriko.higuchi@takeda.com
or
Media
Relations
Japanese media
Tsuyoshi Tada, +81
(0)3-3278-2417
tsuyoshi.tada@takeda.com
or
Media
outside Japan
Jocelyn Gerst, +1-224-554-5542
jocelyn.gerst@takeda.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
